These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17002485)

  • 1. Anticoagulation for stroke prevention: high effectiveness, more cost benefit?
    Shantsila E; Watson T; Lip GY
    Pharmacoeconomics; 2006; 24(10):1035-8. PubMed ID: 17002485
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
    Sullivan PW; Arant TW; Ellis SL; Ulrich H
    Pharmacoeconomics; 2006; 24(10):1021-33. PubMed ID: 17002484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting patients with atrial fibrillation and improving their anticoagulation management.
    Kamath S; Lip GY
    Clin Cardiol; 2001 May; 24(5):355-7. PubMed ID: 11346241
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral anticoagulation and stroke in atrial fibrillation.
    Epstein EF; Natarajan I
    N Engl J Med; 2003 Dec; 349(24):2360-1; author reply 2360-1. PubMed ID: 14674042
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral anticoagulation and stroke in atrial fibrillation.
    Boos CJ
    N Engl J Med; 2003 Dec; 349(24):2360-1; author reply 2360-1. PubMed ID: 14674043
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
    Singh SM; Wijeysundera HC
    Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. South Africa's poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):220. PubMed ID: 21881695
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recent development of anticoagulation in stroke prevention for atrial fibrillation].
    Suzuki S; Yamashita T
    Nihon Rinsho; 2014 Jul; 72(7):1282-6. PubMed ID: 25163322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke in atrial fibrillation: a need for effective anticoagulation.
    Bhatia V
    South Med J; 2004 Oct; 97(10):919-20. PubMed ID: 15558912
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of ximelagatran for stroke prevention.
    Perret-Guillaume C; Wahl D
    JAMA; 2005 Jun; 293(23):2860-1; author reply 2861. PubMed ID: 15956626
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
    Palagummi P; Saltzman H; Ezekowitz M
    Am Heart J; 2005 Jan; 149(1 Suppl):S32-5. PubMed ID: 15644791
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustainability and impact of warfarin compliance for atrial fibrillation.
    Kuo S; Burrill J
    Med Health R I; 2007 Dec; 90(12):378-80. PubMed ID: 18314828
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of atrial fibrillation and stroke prevention.
    Bushnell CD; Matchar DB
    Am J Manag Care; 2004 Apr; 10(3 Suppl):S66-71. PubMed ID: 15152748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.